Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, July 1999, p. 1803-1804, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Sensitivity of Amoxicillin-Resistant
Helicobacter pylori to Other Penicillins
Maria P.
Dore,1,*
David Y.
Graham,1
Antonia R.
Sepulveda,1
Giuseppe
Realdi,2 and
Michael
S.
Osato1
Department of Medicine, VA Medical Center,
and Baylor College of Medicine, Houston, Texas
77030,1 and Department of Internal
Medicine, University of Sassari, Sassari, Italy 071002
Received 24 November 1998/Returned for modification 8 March
1999/Accepted 7 May 1999
 |
ABSTRACT |
The sensitivities to penicillins and to a penicillin and
-lactamase inhibitor combination agent were determined for
Helicobacter pylori strains that were sensitive, moderately
resistant, or highly resistant to amoxicillin. All strains were
resistant to nafcillin and oxacillin. Moderately resistant strains
showed an intermediate zone of inhibition to ticarcillin, mezlocillin,
piperacillin, and amoxicillin-clavulanic acid. High-level resistance
was associated with the smallest zone size for all penicillins tested.
 |
TEXT |
The reliable treatment of
Helicobacter pylori infection has been difficult, and
successful regimens generally require two or more antimicrobial drugs
coupled with an acid inhibitor (3, 6). Results with the dual
therapy that combined omeprazole with amoxicillin have varied widely
(8-10). We have recently identified amoxicillin-resistant
H. pylori bacteria from patients from both the United States
and Italy (1). This study investigated the sensitivity
patterns of these H. pylori isolates to different penicillins.
Isolates.
Six amoxicillin-resistant H. pylori
strains isolated from three patients with peptic ulcers from the United
States and 14 amoxicillin-resistant strains isolated from dyspeptic
patients from Sardinia, Italy, were used. The strains were stored at
80°C for 5 to 10 months in cysteine-Albimi broth medium containing 20% glycerol (4). Before and after storage at
80°C, the
MIC of amoxicillin was assessed by the E-test method (4).
-Lactamase assay.
The chromogenic cephalosporin method was
used to test for the production of
-lactamase. Cefinase disks
(Becton Dickinson Microbiology Systems, Cockeysville, Md.) impregnated
with nitrocefin, a chromogenic cephalosporin, were moistened with a
drop of sterile distilled water. Several well-isolated colonies of
H. pylori from the agar plate were selected and smeared over
the disk surface.
-Lactamase activity was identified by a change in
the color of the chromogenic cephalosporin after incubation at room
temperature for up to 2 h. Staphylococcus aureus (ATCC
29213) served as the positive control (7).
Amoxicillin gradient plates.
Frozen strains that were
amoxicillin resistant prestorage, as well as strains that were never
resistant to amoxicillin, were cultured onto brain heart infusion
(Difco Laboratories, Detroit, Mich.) agar plates containing 7%
defibrinated horse blood (Cocalico Biologicals, Reamstown, Pa.) (BHIB
agar plates) and incubated for 3 to 5 days at 37°C in 12%
CO2 and 100% relative humidity. Amoxicillin resistance in
amoxicillin-tolerant H. pylori bacteria was restored by
using a modification of the method described by Kim and Anthony
(5) as previously described (1).
Bacterial suspensions.
The H. pylori strains used
in this study were (i) five prestorage amoxicillin-resistant H. pylori isolates (SS234, SS260, SS158, SS211, and BLMA)
characterized by high levels of amoxicillin resistance (32 µg/ml
determined on gradient plates), (ii) 12 prestorage amoxicillin-resistant H. pylori isolates (SS47, SS70, SS128,
SS130, SS93, SS96, SS263, BLMC, WLRA, WLRC, 93IAA, and 93IAC) for which MICs were 2 µg/ml, and (iii) three amoxicillin-sensitive strains (Mp4, SS204, and SS88) for which MICs were 0.016 µg/ml. All H. pylori isolates were grown on BHIB plates for 3 to 4 days at
37°C in 12% CO2 and 100% relative humidity. Each plate
was swabbed with a cell suspension in sterile saline equivalent to a
2.0 McFarland standard.
Antibiotics tested included ampicillin (10 µg), penicillin (2 IU),
oxacillin (1 mg), ticarcillin (75 mg), mezlocillin (75 mg), nafcillin
(1 mg), piperacillin (100 mg), and amoxicillin-clavulanic acid (10 and
20 mg) (BBL, Becton Dickinson Microbiology Systems). Mueller-Hinton
agar plates (diameter, 150 mm) containing 5% sheep blood (BBL) were
covered with each cell suspension to produce a lawn of bacterial
growth. Disks were aseptically placed onto the dried surfaces of the
inoculated plates. The diameters of the zones of inhibition were
measured after incubation at 37°C for 72 to 96 h in an
atmosphere with 100% relative humidity and 12% CO2. All
disk diffusion tests were performed in duplicate.
There are no standard, published, disk zone diameter breakpoints for
any antimicrobial agent for
H. pylori. For each antibiotic,
the mean zone diameters were taken as the inhibitory
zone.
Twenty
H. pylori strains obtained prior to antibiotic
therapy from 17 patients were used in this study. Seventeen isolates
were initially resistant to amoxicillin, with MICs for all strains
greater than 256 µg/ml, as determined by the E test. The
susceptibility
to amoxicillin was also tested by using the agar
dilution method,
and similar levels of resistance were determined
(unpublished
data).
No

-lactamase activity was detected in any of the
amoxicillin-resistant
H. pylori strains by the nitrocefin
assay. When we
used an adaptation of the gradient agar plate method
previously
described (
5), five resistant strains grew in
media containing
32 µg of amoxicillin per ml and 12 strains grew in
media containing
2 µg of amoxicillin per ml. All
H. pylori
strains regardless of
their sensitivity to amoxicillin were resistant
to nafcillin and
oxacillin as determined by their almost complete lack
of inhibition
zones (

7.6 mm) (Table
1).
Isolates sensitive to amoxicillin
showed the largest zones of
inhibition with all other penicillins
tested. All strains with a high
level of amoxicillin resistance
(

32 µg/ml) showed the smallest
inhibition zone diameters against
all penicillins tested (Table
1). The
12 strains for which amoxicillin
MICs were 2 µg/ml demonstrated zone
diameters with ticarcillin,
mezlocillin, piperacillin, and
amoxicillin-clavulanic acid that
were of intermediate size.
Of 121 treatment studies of omeprazole plus amoxicillin (4,137 patients) the intention-to-treat analysis showed that the cure
of
H. pylori infection averaged only 59% (95% confidence
interval,
58 to 61%). The overall eradication rate (total of 5,725 patients)
was 61% (95% confidence interval, 59 to 62%)
(
8). Resistance
to penicillins occurs by the decreased
activity of

-lactamases,
the binding of the antibiotic to target
penicillin-binding proteins
(PBPs), possible efflux mechanisms, or
outer membrane permeability,
especially in gram-negative bacteria. The
resistance of these
H. pylori isolates was not due to

-lactamase production. Amoxicillin
resistance was associated with
minimal bactericidal concentration/MIC
ratios of

32, indicating that
H. pylori bacteria resistant to
amoxicillin demonstrated a
tolerance to the antibiotic (
1).
PBPs are a set of enzymes responsible for the terminal stages of
peptidoglycan biosynthesis. PBPs are also a group of target
enzymes for
the

-lactam antibiotic family. Amoxicillin-tolerant
H. pylori strains with high levels of amoxicillin resistance showed
cross-resistance to all the other penicillins tested, consistent
with
our observation that penicillin-resistant
H. pylori bacteria
lack a PBP with a molecular weight of 30,000 to 32,000, termed
PBP D
(
2). It appears likely that alterations in PBPs might
affect
the sensitivity to all penicillins tested, not just amoxicillin
or
penicillin, such that cross-resistance to other penicillins
excludes
the possibility of replacing amoxicillin with other penicillins.
Amoxicillin resistance among
H. pylori strains may reflect
the
indiscriminate use of

-lactam
antibiotics.
 |
ACKNOWLEDGMENTS |
This work was supported by the Department of Veterans Affairs and
by the generous support of Hilda Schwartz.
We are thankful for the contribution of Siddarta Reddy, VAMC and Baylor
College of Medicine, Houston, Texas.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Medicine, VA Medical Center (111D), 2002 Holcombe Blvd., Houston, TX 77030. Phone: (713) 794-7233. Fax: (713) 795-4471. E-mail:
mariap{at}bcm.tmc.edu.
 |
REFERENCES |
| 1.
|
Dore, M. P.,
M. S. Osato,
G. Realdi,
I. Mura,
D. Y. Graham, and A. R. Sepulveda.
1999.
Amoxicillin tolerance in Helicobacter pylori.
J. Antimicrob. Chemother.
43:47-54[Abstract/Free Full Text].
|
| 2.
|
Dore, M. P.,
D. Y. Graham, and A. R. Sepulveda.
1998.
PBP-D, a novel penicillin-binding protein is involved in amoxicillin resistance in Helicobacter pylori.
Gastroenterology
114:A-109. (Abstract.)
|
| 3.
|
Graham, D. Y.,
W. A. de Boer, and G. N. Tytgat.
1996.
Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance.
Am. J. Gastroenterol.
91:1072-1076[Medline].
|
| 4.
|
Hachem, C. Y.,
J. E. Clarridge,
R. Reddy,
R. Flamm,
D. G. Evans,
S. K. Tanaka, and D. Y. Graham.
1996.
Antimicrobial susceptibility testing of Helicobacter pylori. Comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole.
Diagn. Microbiol. Infect. Dis.
24:37-41[Medline].
|
| 5.
|
Kim, K. S., and B. F. Anthony.
1983.
Use of penicillin-gradient and replicate plates for the demonstration of tolerance to penicillin in streptococci.
J. Infect. Dis.
148:488-491[Medline].
|
| 6.
|
Megraud, F.
1997.
Resistance of Helicobacter pylori to antibiotics.
Aliment. Pharmacol. Ther.
11(Suppl. 1):43-53.
|
| 7.
|
O'Callaghan, C. H.,
A. Morris,
S. M. Kirby, and A. H. Shingler.
1972.
Novel method for detection of -lactamases by using a chromogenic cephalosporin substrate.
Antimicrob. Agents Chemother.
1:283-288[Abstract/Free Full Text].
|
| 8.
|
Penston, J. G., and K. E. L. McColl.
1997.
Eradication of Helicobacter pylori: an objective assessment of current therapies.
Br. J. Clin. Pharmacol.
43:223-243[Medline].
|
| 9.
|
Unge, P.
1996.
Review of Helicobacter pylori eradication regimens.
Scand. J. Gastroenterol.
31(Suppl. 215):74-81[Medline].
|
| 10.
|
van der Hulst, R. W. M.,
J. J. Keller,
E. A. J. Raws, and G. N. J. Tytgat.
1996.
Treatment of Helicobacter pylori infection in humans: a review of the world literature.
Helicobacter
1:6-19[Medline].
|
Antimicrobial Agents and Chemotherapy, July 1999, p. 1803-1804, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kamoda, O., Anzai, K., Mizoguchi, J.-i., Shiojiri, M., Yanagi, T., Nishino, T., Kamiya, S.
(2006). In Vitro Activity of a Novel Antimicrobial Agent, TG44, for Treatment of Helicobacter pylori Infection.. Antimicrob. Agents Chemother.
50: 3062-3069
[Abstract]
[Full Text]
-
DeLoney, C. R., Schiller, N. L.
(2000). Characterization of an In Vitro-Selected Amoxicillin-Resistant Strain of Helicobacter pylori. Antimicrob. Agents Chemother.
44: 3368-3373
[Abstract]
[Full Text]